Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
Lyell reported a Q2 net loss of $44.8 million, ending the quarter with $228.0 million in cash and marketable securities, which management expects to fund operations into Q3 2027. The PiNACLE pivotal trial of ronde-cel remains on track for pivotal data in mid-2027 and a BLA submission in the second half of 2027, with updated safety data showing no Grade ≥ 3 CRS and a 97% manufacturing success rate.
Key figures
- Revenue
- 4000
- Ga Expenses
- 9600000
- Rd Expenses
- 39500000
- Cash Position
- 228000000
- Runway
- Q3 2027
- Ronde cel grade 3 crs
- 0
- Ronde cel manufacturing success rate
- 97%
- Lyl273 grade 2 diarrhea rate with prophylaxis
- 10%
- Lyl273 grade 2 diarrhea rate without prophylaxis
- 55%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.